Stock Analiz

Genmab A (GMAB) earnings: date, estimates and history

Price $51.37 · data as of November 13, 2026

Next earnings report

Next reportNot announced yet
Quarterending December 31, 2026
EPS estimate$0.20
Revenue estimate$8.4B
Expected EPS growth—

The date appears here once Genmab A confirms it, usually two to four weeks before the report.

Track record

Beat EPS estimates3 of 4
Average surprise+32.6%
Average move on report day±4.1%

Genmab A beat the consensus earnings estimate in 3 of its last 4 reports, by +32.6% on average. On report days the stock moved 4.1% on average, up or down.

Earnings history

ReportedEPS estimateEPS actualSurpriseRevenueRevenue growthStock move
November 5, 2026
Sep/2026
$0.32$0.55+70.5%——−2.7%
August 6, 2026
Jun/2026
$0.33$0.49+47.5%——+6.8%
May 7, 2026
Mar/2026
$0.19$0.13−29.7%——−5.2%
November 6, 2025
Sep/2025
$0.45$0.65+42.3%——−1.8%

EPS as compared with analyst estimates (adjusted EPS). Revenue growth is against the same quarter a year earlier. Stock move: change on the first trading day after the report.

Frequently asked questions

When is Genmab A’s next earnings date?

Genmab A has not confirmed its next report date yet. Its last report was on November 5, 2026.

Did Genmab A beat earnings last quarter?

Yes, it reported EPS of $0.55 on November 5, 2026 against an estimate of $0.32 (a +70.5% surprise), and the stock moved −2.7% the next trading day.

What EPS do analysts expect next quarter?

The consensus estimate is $0.20 per share on revenue of about $8.4B.

Report dates and estimates from analyst consensus data; results from company reports. Updated daily. Not investment advice. Earnings calendar